Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis

OBJECTIVE: The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaoting, Weng, Xiuhua, Lin, Shen, Liu, Yiwei, Luo, Shaohong, Wang, Hang, Ming, Wai-kit, Huang, Pinfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462248/
https://www.ncbi.nlm.nih.gov/pubmed/32868353
http://dx.doi.org/10.1136/bmjopen-2019-036107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462248/
https://www.ncbi.nlm.nih.gov/pubmed/32868353
http://dx.doi.org/10.1136/bmjopen-2019-036107

Ejemplares similares